| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10486383 | Value in Health | 2011 | 6 Pages |
Abstract
As the ICER fell within the cost per QALY range for many other widely used oncology medicines, everolimus is projected to be a cost-effective treatment relative to sorafenib for sunitinib-refractory mRCC.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Roman MS, Maruit MPH, Giuseppe MD, PhD, Zhimei PhD, Jean-Francois MBA, Xufang MBA, MD, Justin MA, Lou PhD,